Isolation of Mycobacterium talmoniae from a patient with diffuse panbronchiolitis: a case report.
Diffuse panbronchiolitis
Drug-susceptibility
Mycobacterium talmoniae
Non-tuberculous mycobacteria
Standard combination therapy
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
10 Mar 2021
10 Mar 2021
Historique:
received:
19
06
2020
accepted:
01
03
2021
entrez:
11
3
2021
pubmed:
12
3
2021
medline:
10
4
2021
Statut:
epublish
Résumé
Mycobacterium (M) talmoniae isolated from a patient with cystic fibrosis was first described in 2017, and cases of M. talmoniae remain exceedingly rare. A 51-year-old woman had respiratory symptoms for 10 years. Diffuse panbronchiolitis (DPB) was detected at the first visit at our hospital. A cavity lesion in the apex of the left lung was found, and sputum and bronchoalveolar lavage fluid were acid-fast bacillus (AFB) smear- and culture-positive besides Pseudomonas aeruginosa. M. talmoniae was finally identified, and the standard combination therapy for non-tuberculous mycobacteria (NTM) was administered for 2 y referring to the drug-susceptibility test. Thereafter, the AFB culture was negative, the wall thickness of the lung cavity was ameliorated, and oxygen saturation improved. We encountered a rare case of M. talmoniae with DPB, for which standard combination therapy was effective. M. talmoniae may be considered a potential pathogen of lung disease, especially in patients with bronchiectatic lesions.
Sections du résumé
BACKGROUND
BACKGROUND
Mycobacterium (M) talmoniae isolated from a patient with cystic fibrosis was first described in 2017, and cases of M. talmoniae remain exceedingly rare.
CASE PRESENTATION
METHODS
A 51-year-old woman had respiratory symptoms for 10 years. Diffuse panbronchiolitis (DPB) was detected at the first visit at our hospital. A cavity lesion in the apex of the left lung was found, and sputum and bronchoalveolar lavage fluid were acid-fast bacillus (AFB) smear- and culture-positive besides Pseudomonas aeruginosa. M. talmoniae was finally identified, and the standard combination therapy for non-tuberculous mycobacteria (NTM) was administered for 2 y referring to the drug-susceptibility test. Thereafter, the AFB culture was negative, the wall thickness of the lung cavity was ameliorated, and oxygen saturation improved.
CONCLUSIONS
CONCLUSIONS
We encountered a rare case of M. talmoniae with DPB, for which standard combination therapy was effective. M. talmoniae may be considered a potential pathogen of lung disease, especially in patients with bronchiectatic lesions.
Identifiants
pubmed: 33691626
doi: 10.1186/s12879-021-05944-9
pii: 10.1186/s12879-021-05944-9
pmc: PMC7945688
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
251Références
Respirology. 2015 Jan;20(1):80-6
pubmed: 25269823
Respirology. 2011 May;16(4):581-8
pubmed: 21303426
Naika. 1969 Mar;23(3):442-51
pubmed: 5783341
Nihon Kokyuki Gakkai Zasshi. 2002 Feb;40(2):149-53
pubmed: 11974871
Arch Bronconeumol. 2012 May;48(5):184-5
pubmed: 22349095
Am J Respir Med. 2002;1(2):119-31
pubmed: 14720066
Eur Respir J. 2006 Oct;28(4):862-71
pubmed: 17012632
Int J Syst Evol Microbiol. 2017 Aug;67(8):2640-2645
pubmed: 28809146
J Clin Pathol. 1993 Mar;46(3):271-2
pubmed: 8463423
Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1829-32
pubmed: 9620913
Am J Respir Crit Care Med. 2003 Mar 15;167(6):828-34
pubmed: 12433668
Cochrane Database Syst Rev. 2015 Jan 25;1:CD007716
pubmed: 25618845
Intern Med. 2020 Nov 15;59(22):2811-2815
pubmed: 32641662
Emerg Infect Dis. 2016 Jun;22(6):1116-7
pubmed: 27191735
J Clin Microbiol. 2019 Jan 30;57(2):
pubmed: 30429252
Clin Chest Med. 2002 Sep;23(3):643-53
pubmed: 12371000
Kekkaku. 2004 Dec;79(12):737-41
pubmed: 15782619
Chest. 1983 Jan;83(1):63-9
pubmed: 6848335